Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1961 3
1962 1
1964 2
1965 4
1966 1
1967 4
1968 3
1969 8
1970 4
1971 5
1972 5
1973 8
1974 4
1975 11
1976 12
1977 13
1978 19
1979 17
1980 18
1981 16
1982 15
1983 23
1984 34
1985 33
1986 37
1987 35
1988 36
1989 39
1990 49
1991 61
1992 62
1993 65
1994 80
1995 82
1996 96
1997 86
1998 119
1999 85
2000 97
2001 106
2002 108
2003 151
2004 134
2005 160
2006 177
2007 198
2008 179
2009 206
2010 227
2011 258
2012 288
2013 306
2014 347
2015 358
2016 397
2017 415
2018 420
2019 498
2020 553
2021 672
2022 527
2023 533
2024 248

Text availability

Article attribute

Article type

Publication date

Search Results

7,690 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Interstitial lung disease 2"
Page 1
Interstitial lung disease.
Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Antoniou KM, et al. Eur Respir Rev. 2014 Mar 1;23(131):40-54. doi: 10.1183/09059180.00009113. Eur Respir Rev. 2014. PMID: 24591661 Free PMC article. Review.
Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. ...Early diagnosis and disease stratification is also important in the field of other interstitial lung …
Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidi …
Interstitial Lung Disease: A Review.
Maher TM. Maher TM. JAMA. 2024 May 21;331(19):1655-1665. doi: 10.1001/jama.2024.3669. JAMA. 2024. PMID: 38648021 Review.
IMPORTANCE: Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. .. …
IMPORTANCE: Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation an …
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.
Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, Tarsia P, Cattelan A, Comes A, De Laurentiis M, Falcone A, Regge D, Richeldi L, Siena S. Conte P, et al. ESMO Open. 2022 Apr;7(2):100404. doi: 10.1016/j.esmoop.2022.100404. Epub 2022 Feb 24. ESMO Open. 2022. PMID: 35219244 Free PMC article. Review.
BACKGROUND: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. ...Important components of the diagnostic p …
BACKGROUND: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease …
Contemporary Concise Review 2021: Interstitial lung disease.
McCarthy C, Keane MP. McCarthy C, et al. Respirology. 2022 Jul;27(7):539-548. doi: 10.1111/resp.14278. Epub 2022 May 5. Respirology. 2022. PMID: 35513341 Free PMC article. Review.
Despite the significant impact of the SARS-CoV-2 pandemic on patients, clinicians and communities, advances in the care and understanding of interstitial lung disease (ILD) continued unabated. Recent studies have led to improved guidelines, better understandi …
Despite the significant impact of the SARS-CoV-2 pandemic on patients, clinicians and communities, advances in the care and understanding of …
Interstitial Lung Diseases in Developing Countries.
Rivera-Ortega P, Molina-Molina M. Rivera-Ortega P, et al. Ann Glob Health. 2019 Jan 22;85(1):4. doi: 10.5334/aogh.2414. Ann Glob Health. 2019. PMID: 30741505 Free PMC article. Review.
More than 100 different conditions are grouped under the term interstitial lung disease (ILD). A diagnosis of an ILD primarily relies on a combination of clinical, radiological, and pathological criteria, which should be evaluated by a multidisciplinary team …
More than 100 different conditions are grouped under the term interstitial lung disease (ILD). A diagnosis of an ILD pr …
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V. Nasser M, et al. Eur Respir J. 2021 Feb 11;57(2):2002718. doi: 10.1183/13993003.02718-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 32943410 Free PMC article.
In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking.We assessed the characterist …
In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may deve …
The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.
Wang Y, Chen S, Zheng S, Lin J, Hu S, Zhuang J, Lin Q, Xie X, Zheng K, Zhang W, Du G, Zhang G, Hoffmann-Vold AM, Matucci-Cerinic M, Furst DE. Wang Y, et al. Arthritis Res Ther. 2021 Aug 14;23(1):212. doi: 10.1186/s13075-021-02586-9. Arthritis Res Ther. 2021. PMID: 34391465 Free PMC article. Review.
Screening and follow-up of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is a challenge in clinical practice. ...If RA-ILD can be identified early, there may be an opportunity for an early treatment and close follow-up that might del …
Screening and follow-up of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is a challenge in cl …
Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR, Vilbert M, Rosa VDL, Oliveira JL, Deus MM, Freitas-Junior R. Soares LR, et al. ESMO Open. 2023 Aug;8(4):101613. doi: 10.1016/j.esmoop.2023.101613. Epub 2023 Jul 23. ESMO Open. 2023. PMID: 37481956 Free PMC article.
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has been shown to benefit progression-free survival and overall survival in patients with metastatic breast cancer (mBC) after progression on 1 human epidermal growth factor receptor 2 (HER2)-targeted therapies. However, interstitial …
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has been shown to benefit progression-free survival and overall survival in patients with metasta …
ABCA3-related interstitial lung disease beyond infancy.
Li Y, Seidl E, Knoflach K, Gothe F, Forstner ME, Michel K, Pawlita I, Gesenhues F, Sattler F, Yang X, Kroener C, Reu-Hofer S, Ley-Zaporozhan J, Kammer B, Krüger-Stollfuß I, Dinkel J, Carlens J, Wetzke M, Moreno-Galdó A, Torrent-Vernetta A, Lange J, Krenke K, Rumman N, Mayell S, Sismanlar T, Aslan A, Regamey N, Proesmans M, Stehling F, Naehrlich L, Ayse K, Becker S, Koerner-Rettberg C, Plattner E, Manali ED, Papiris SA, Campo I, Kappler M, Schwerk N, Griese M. Li Y, et al. Thorax. 2023 Jun;78(6):587-595. doi: 10.1136/thorax-2022-219434. Epub 2023 Feb 20. Thorax. 2023. PMID: 36808083 Free PMC article.
BACKGROUND: The majority of patients with childhood interstitial lung disease (chILD) caused by pathogenic variants in ATP binding cassette subfamily A member 3 (ABCA3) develop severe respiratory insufficiency within their first year of life and succumb to …
BACKGROUND: The majority of patients with childhood interstitial lung disease (chILD) caused by pathogenic variants in …
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators. Vancheri C, et al. Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC. Am J Respir Crit Care Med. 2018. PMID: 28889759 Clinical Trial.
RATIONALE: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. ...METHODS: Patients wit …
RATIONALE: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues to progr …
7,690 results